Passive immunization against β-amyloid (Aβ) has become an increasingly desirable strategy
as a therapeutic treatment for Alzheimer's disease (AD). However, traditional passive …

Reducing production of amyloid-β (Aβ) peptide by direct inhibition of the enzymes that process
amyloid precursor protein (APP) is a central therapeutic strategy for treating Alzheimer’s …

The pharmacokinetics (PK) of therapeutic antibodies is determined by target and non-target
mediated mechanisms. These antibody-specific factors need to be considered during …

… rh Y24L/Y31A IGF-1 (50 μg/dL) alone significantly increased epiphyseal plate width (controls
of … variant (50 μg/dL), variant (50 μg/dL) combined with rhGH (10 μg/dL), rhGH alone (10 μg/…

To address the role of the GH-binding protein (GHBP) in GH physiology, two forms of
recombinant human GHBP (rhGHBP) were given alone or in combination with rhGH to …

The long-term effects of recombinant human insulin-like growth factor-I (rhIGF-I) and GH (rhGH)
on body growth and the IGF-I/IGF binding protein (IGFBP)/acid-labile subunit (ALS) axis …

Modulating the binding affinities to IgE or changing the FcγR binding properties of anti-IgE
antibodies offers an opportunity to enhance the therapeutic potential of anti-IgE antibodies, …

Efalizumab pharmacokinetics, pharmacodynamics, and efficacy were assessed after
subcutaneous administration of 1.0 or 2.0 mg/kg/wk for 12 weeks with 12 weeks of follow‐up in …

Besides stimulating GH release, some GH secretagogues also release ACTH and adrenal
steroids. Several novel classes of potent GH secretagogues have recently been described, …

We describe a new animal model of obesity and GH deficiency and report the effects on
body fat of administering (GH) and insulin-like growth factor (IGF-I) in the model. Female GH-…